Whence interferon? Variety in the production of interferon in response to viral infection.
about
Induction and function of type I and III interferon in response to viral infectionSTAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptorTissue-specific positive feedback requirements for production of type I interferon following virus infectionNegative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production.IFNs and STATs in innate immunity to microorganisms.Immunological mechanisms of vaccination.Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis.Role of interferons in the treatment of severe acute respiratory syndrome.In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice.Immunomodulatory therapy for chronic hepatitis B virus infection.Peptide-based therapeutic vaccines for allergic and autoimmune diseases.Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo.Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo.The yin and yang of type I interferon activity in bacterial infection.HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I.GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survivalAfrican swine fever virus multigene family 360 and 530 genes affect host interferon response.A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response.Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.Reverse transcription real-time PCR for detection of porcine interferon α and β genes.Regulation of Stat3 nuclear export.Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9.Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.Inhibition of the interferon antiviral response by hepatitis C virus.
P2860
Q27010065-7CCC0B1F-0036-44C8-A8FC-9182D2F0D63CQ27312177-8B147E49-02E4-4B57-99F8-67326140F8B7Q33881880-1864BF9A-B40A-4686-A8B1-2A5E4F45D455Q33924436-4A8EB6EB-006D-40F1-8C8F-AB8F68B875E7Q34647015-FA860A2C-04B3-450A-B3AB-0FA409F9B9EBQ35659533-5E380735-6E90-47FD-A0A0-E4A86DFD52CEQ35675517-07150F05-1E79-4055-B757-88B22D347332Q35790834-978EB5D4-F694-4B66-A906-709DBAC04653Q35848213-3B6B5FD7-BEF3-48B8-BE8C-452594E50A4AQ36014956-6F785F73-DF5A-404C-A4BA-CDD60C5C6B72Q36090197-9C563B4D-98D5-4DE6-BA9F-0FD1942A9F55Q36098849-4F9DC5D4-8428-48FD-9176-C44E4ABAAB8DQ36229426-AFEB6E59-33E6-4000-B128-D8DE448586C5Q36234715-D8B53D61-35B5-4F19-916A-0B9E8BF8AFBEQ36584342-1F1580A9-E1EE-4ACD-999C-FDC47564049FQ36916371-6F6C9B55-77FC-4CFD-A335-C76D10401A8AQ36959744-8A31BF3B-D8E9-4222-B3E6-9C0F2318A166Q38357901-317CEC9E-AA24-4D06-B20A-4F437C3B7FB9Q38450454-763206C9-7891-471E-8940-E420848A096FQ39529990-02FD6C96-E336-4C8D-B9EB-3DBB39AB2C80Q39741143-5D8AAA60-B013-4CFD-9DEA-5B47B78427F7Q40088398-B5770089-0515-4EDE-88BA-3890665DDC75Q40488939-68B9813C-9ACD-43C8-A56C-A6340C354919Q45375947-43C4D491-DC76-4204-AA10-CF1FD2832337
P2860
Whence interferon? Variety in the production of interferon in response to viral infection.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Whence interferon? Variety in ...... n response to viral infection.
@ast
Whence interferon? Variety in ...... n response to viral infection.
@en
type
label
Whence interferon? Variety in ...... n response to viral infection.
@ast
Whence interferon? Variety in ...... n response to viral infection.
@en
prefLabel
Whence interferon? Variety in ...... n response to viral infection.
@ast
Whence interferon? Variety in ...... n response to viral infection.
@en
P2860
P356
P1476
Whence interferon? Variety in the production of interferon in response to viral infection
@en
P2093
David E Levy
P2860
P356
10.1084/JEM.20020075
P407
P50
P577
2002-02-01T00:00:00Z